Privately owned biotech company Symphogen has chosen TransPerfect Life Sciences’ Trial Interactive (TI) GlobalLearn learning management system to simplify learning in clinical trials.
Symphogen is engaged in advancing superior monoclonal antibodies (mAb) therapeutics for oncology and immuno-oncology.
The system will allow Symphogen to provide critical compliance-focused training programmes to research personnel. This will help in meeting regulatory standards, as well as meet the expectations of the Food and Drug Administration (FDA) and sponsors.
The company noted that study personnel are required to ensure effective knowledge transfer on protocols, amendments, and other critical study content.
Symphogen has selected TI GlobalLearn for its clinical research compliance and the effective creation and remote training rollout.
TransPerfect’s TI e-clinical platform provides end-to-end clinical research lifecycle solutions, including site selection and activation, clinical content collaboration, and e-learning.
By combining compliance learning and content collaboration, TI GlobalLearn enables sponsors and contract research organisations (CROs) to increase savings in study training logistics.
According to TransPerfect, this integrated experience creates a streamlined process from clinical document authoring, review and approval, to training delivery to archival in the electronic trial master file (eTMF).
TransPerfect president and CEO Phil Shawe said: “Symphogen is a forward-thinking organisation and is continually building its culture of quality and inspection readiness.
“GlobalLearn enhances the e-clinical experience by ensuring that the knowledge necessary to conduct studies efficiently and within the framework of regulatory compliance is shared among all relevant stakeholders.”
